A sense of urgency: evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies.
Cheng, S. K., Dietrich, M. S., & Dilts, D. M. (2010). A sense of urgency: evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies. Clinical Cancer Research, 16(22), 5557-5563.
Predicting accrual achievement: monitoring accrual milestones of NCI-CTEP–sponsored clinical trials. Clinical Cancer Research,
Cheng, S. K., Dietrich, M. S., & Dilts, D. M. (2011). Predicting accrual achievement: monitoring accrual milestones of NCI-CTEP–sponsored clinical trials. Clinical Cancer Research, 17(7), 1947-1955.
Characteristics of oncology clinical trials: insights from a systematic analysis of ClinicalTrials. gov
Hirsch, B. R., Califf, R. M., Cheng, S. K., Tasneem, A., Horton, J., Chiswell, K., ... & Abernethy, A. P. (2013). Characteristics of oncology clinical trials: insights from a systematic analysis of ClinicalTrials. gov. JAMA internal medicine, 173(11), 972-979.
The importance of doing trials right while doing the right trials. Clinical Cancer Research,
Dilts, D. M., & Cheng, S. K. (2012). The importance of doing trials right while doing the right trials. Clinical Cancer Research, 18(1), 3-5.
Building expertise in translational processes through partnerships with schools of business. In Translational Medicine-What, Why and How: An International Perspective
Cheng, S. K., & Dilts, D. M. (2012). Building expertise in translational processes through partnerships with schools of business. In Translational Medicine-What, Why and How: An International Perspective (Vol. 3, pp. 74-81). Karger Publishers.
The Prevalence and Economic Impact of Low Enrolling Clinical Studies At An Academic Medical Center
Kitterman, D. R., Cheng, S. K., Dilts, D. M., & Orwoll, E. S. (2011). The prevalence and economic impact of low-enrolling clinical studies at an academic medical center. Academic medicine: journal of the Association of American Medical Colleges, 86(11), 1360.
Phase III clinical trial development: a process of chutes and ladders. Clinical Cancer Research,
Dilts, D. M., Cheng, S. K., Crites, J. S., Sandler, A. B., & Doroshow, J. H. (2010). Phase III clinical trial development: a process of chutes and ladders. Clinical Cancer Research, 16(22), 5381-5389.
Of Baseball, Medical Decision Making, and Innumeracy.
FERRANTI, L., CHENG, S., & DILTS, D. (2010). Of Baseball, Medical Decision Making, and Innumeracy. HANDBOOK OF DECISION MAKING, 501.
Steps and time to process clinical trials at the Cancer Therapy Evaluation Program.
Dilts, D. M., Sandler, A. B., Cheng, S. K., Crites, J. S., Ferranti, L. B., Wu, A. Y., ... & Abrams, J. (2009). Steps and time to process clinical trials at the Cancer Therapy Evaluation Program. Journal of Clinical Oncology, 27(11), 1761-1766.
Development of clinical trials in a cooperative group setting: The Eastern Cooperative Oncology Group.
Dilts, D. M., Sandler, A., Cheng, S., Crites, J., Ferranti, L., Wu, A., ... & Comis, R. (2008). Development of clinical trials in a cooperative group setting: The Eastern Cooperative Oncology Group. Clinical Cancer Research, 14(11), 3427-3433.
Processes to activate phase III clinical trials in a Cooperative Oncology Group: the Case of Cancer and Leukemia Group B.
Dilts, D. M., Sandler, A. B., Baker, M., Cheng, S. K., George, S. L., Karas, K. S., ... & Scoggins, M. (2006). Processes to activate phase III clinical trials in a Cooperative Oncology Group: the Case of Cancer and Leukemia Group B. Journal of Clinical Oncology, 24(28), 4553-4557.